Pfizer ends vaccine trial with 95% success rate
Pfizer ends vaccine trial with 95% success rate

Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

Soraya Ali reports.